Myriad Genetics
MYGN
197 hedge funds and large institutions have $2.25B invested in Myriad Genetics in 2021 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 53 increasing their positions, 73 reducing their positions, and 25 closing their positions.
118% more call options, than puts
Call options by funds: $5.65M | Put options by funds: $2.59M
51% more capital invested
Capital invested by funds: $1.49B → $2.25B (+$759M)
44% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 25
5% more funds holding
Funds holding: 187 → 197 (+10)
3.11% less ownership
Funds ownership: 99.93% → 96.82% (-3.1%)
27% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 73
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$77.2M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$24.9M |
| 3 |
BlackRock
New York
|
+$20.7M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$13.6M |
| 5 |
EARNEST Partners
Atlanta,
Georgia
|
+$12.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$56.8M |
| 2 |
Morgan Stanley
New York
|
-$41.9M |
| 3 |
GCM
Glenview Capital Management
New York
|
-$31.6M |
| 4 |
D.E. Shaw & Co
New York
|
-$15.8M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$12.7M |
MYGN Hedge Fund Activity: Q1 2021 in Review
197 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q1 2021, worth a combined $2.25B — up 51% from $1.49B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new MYGN positions and 25 closed out — a net gain of 11 holders — while 53 added to existing stakes and 73 trimmed.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $77.2M. The largest seller was Camber Capital Management, cutting an estimated $56.8M.
- 197 institutional investors held Myriad Genetics (MYGN) as of Q1 2021, up from 187 in Q4 2020.
- Funds reported $2.25B of Myriad Genetics stock for Q1 2021, up 51% quarter-over-quarter.
- 36 funds opened new Myriad Genetics positions in Q1 2021 and 25 closed out, a net change of +11 holders.
- The largest Myriad Genetics buyer in Q1 2021 was PFM Health Sciences, an estimated $77.2M added.
- The largest Myriad Genetics seller in Q1 2021 was Camber Capital Management, an estimated $56.8M sold.
Based on aggregated 13F filings for Q1 2021.